<DOC>
	<DOCNO>NCT02786576</DOCNO>
	<brief_summary>This study assess effect adalimumab treatment moderate severe Hidradenitis Suppurativa ( HS ) patient real world setting . The objective study estimate effectiveness adalimumab treatment disease severity , estimate impact adalimumab treatment patient ' quality life , psychological effect , work productivity healthcare resource utilization describe treatment practice study period .</brief_summary>
	<brief_title>Effectiveness Adalimumab Moderate Severe HidrAdenitis SuppuRativa Patients - Multi cOuNtry studY Real Life Setting</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Clinical diagnosis moderate severe Hidradenitis Suppurativa The decision treat adalimumab make physician accordance local label ( Summary Product Characteristics ; product label ) prior decision approach participant participate study Participants willing involved study sign patient authorization form use disclose personal health information ( informed consent , applicable ) Participants clinical interventional study Participants treat adalimumab prior baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Moderate Severe Hidradenitis Suppurativa</keyword>
	<keyword>Adalimumab</keyword>
</DOC>